Rezum Water Vapor Therapy

Rezūm™ Therapy

Five-Year Clinical Data

Proven prostate volume reduction, long-term durability and preservation of sexual function at five years.

Read the study

  

Safe, Effective, Durable

 

Rezūm™ Water Vapor Therapy is now the only in‐office BPH therapy with proven prostate volume reduction and long-term durability out to 5 years while preserving sexual function.1  

The five-year clinical trial, conducted by Kevin McVary, MD and Claus Roehrborn, MD was published in the Journal of Urology in April 2021. 

surgical retreatment
rate through five years1
medication retreatment
rate through five years1
average
procedure time1

  

 

"Rezūm Therapy has been embraced by urology practices, health technology assessment bodies, and urologic societies throughout the US and Europe. This adoption is attributed to the evidence of its clinical advantages, including sustained relief of LUTS, enhanced quality of life, and durability of treatment response."1

 

  

Lasting Relief for Patients

 
BPH disrupts patients’ lives. Our goal is to provide relief that lasts, with a low surgical retreatment rate and while minimizing complications.
Rezūm retreatment rates chart
*Results from different clinical investigations are not directly comparable. Information provided for educational purposes only.
Through five years of follow-up, patients experienced significant improvements to their BPH symptoms. 
 
Convective steam therapy is proven to reduce prostate volume, without thermal lesions occurring outside of the treatment zone.7 Unlike other MISTS, Rezūm™ Therapy is recommended by the AUA for treating MLO.8 And the five-year study affirms a best-in-class surgical retreatment rate of just 4.4%.1 
 
That’s why patients are satisfied with Rezūm Therapy. According to a 4-year single-center study of 255 men, 97% would recommend this treatment to a friend.9

  

The Results

 
The Rezūm pivotal study supports that Rezūm Therapy is a safe and effective in-office BPH treatment that preserves sexual function out to five years, and provides significant, sustained improvement of lower urinary tract symptoms (LUTS) and quality of life for patients suffering from BPH.1

  

Sustained Symptom Relief
Improved Quality of Life
Middle Lobe Obstruction
Versatile Application
Preserves Sexual Function
Proven Safety Profile

Study Details

 

Overview

This was a multicenter (15 sites), randomized, sham-controlled trial of Rezūm Water Vapor Therapy in men with moderate-to-severe LUTS due to benign prostatic hyperplasia (BPH), with the inclusion of the final surgical and BPH medication retreatment rates. Thermal therapy involved injection of water vapor, using the Rezūm System, into obstructive tissue, including the middle lobe and/or enlarged central zone. 

Patient Profile

197 subjects ≥ 50 years old

International Prostate

Symptom Score (IPSS)

Maximum flow rate

(Qmax)

 Prostate volume
≥13
 ≤ 15 ml/s 30-80 cc
Patients were randomized 2:1
(Thermal therapy with the Rezūm System: sham control rigid cystoscopy)
All Rezūm Therapies were completed in the office or ambulatory-surgery center. 

  

Presentation Highlights: Rezūm Therapy Five-Year Clinical Trial

Leading Urologist Kevin McVary, MD, FACS presents the final outcomes of the Rezūm Water Vapor 5-year pivotal study.
Read the study

  

Request More Information

Sign up to learn more about Rezūm Water Vapor Therapy.

 

 

*
*
*
*
*
*
*
*
 
 

  

About Rezūm Therapy

 

Rezūm Water Vapor Therapy uses convective energy to remove obstructive prostate tissue, treating the cause of BPH.   This treatment delivers targeted, controlled doses of the stored thermal energy in water vapor directly to the region of the prostate gland with the obstructive tissue causing the lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). 

 

More Information  

  

Related Content

 
Dr. Kevin McVary
A Closer Look at the Data with Dr. McVary

Read the latest editorial from principal investigator Kevin T. McVary, MD, FACS in the Physician’s Perspectives series. 
Rezūm Therapy Five-Year Clinical Trial Presentation

Watch the full presentation from Kevin McVary, MD, FACS on the final outcomes of the Rezūm Water Vapor 5-year pivotal study.

Indications, Safety and Warnings

References

  1. McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of Rezūm water vapor thermal therapy for treatment of moderate-to-severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2021 Apr 19. Online ahead of print.
  2. Roehrborn CG, Barkin J, Gange SN, et al. Five-year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017 Jun;24(3):8802-13.
  3. Zlotta AR, Giannakopoulos X, Maehlum O, et al. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol. 2003 Jul;44(1):89-93.
  4. Rosario DJ, Phillips JT, Chapple CR. Chapple, Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails.  J Urol. 2007 Mar;177(3):1047-51; discussion 1051.
  5. Hill B, Belville W, Bruskewitz R, et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol. 2004 Jun;171(6 Pt 1):2336-40.
  6. Miller PD, Kastner C, Ramsey EW, et al. Cooled thermotherapy for the treatment of benign prostatic hyperplasia: durability of results obtained with the Targis system. Urology. 2003 Jun;61(6):1160-4.
  7. Mynderse LA, Hanson D, Robb RA, et al. Rezūm System water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology. 2015 Jul;86(1):122-7. 
  8. Parsons JK, Dahm P, Köhler TS, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2020. J Urol. 2020 Oct;204(4):799-804.
  9. Mooney R, Goldberg K, Wong D, et al. Convective radio frequency thermal therapy for treatment of benign prostatic hyperplasia: Singe office experience with 255 patients over 4 years. Urol Pract. 2020 Jan;7(1):28-33. 

The Rezūm System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with BPH. It is indicated for men ≥ 50 years of age with a prostate volume 30cm3 ≤ 80cm3. The Rezūm System is also indicated for treatment of prostate with hyperplasia of the central zone and/or a median lobe. Potential risks associated with Rezūm Water Vapor Therapy include but are not limited to dysuria, hematuria, hematospermia, decrease in ejaculatory volume, suspected urinary tract infection (UTI), urinary frequency, and retention or urgency. 

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

IMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the use of referenced technologies but may not be appropriate for every patient or case. Decisions surrounding patient care depend on the physician’s professional judgment in consideration of all available information for the individual case. Boston Scientific (BSC) does not promote or encourage the use of its devices outside their approved labeling. Case studies are not necessarily representative of clinical outcomes in all cases as individual results may vary.

All images are the property of Boston Scientific. All trademarks are the property of their respective owners.

Top